摘要
二肽基肽酶-4(dipeptidyl-peptidase-4,DPP-4)抑制剂是糖尿病药物治疗领域的突破。目前国内已上市的5种DPP-4抑制剂,包括有西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀。本文从疗效、安全性、特殊人群中的应用及降糖外作用等方面对此类药物进行阐述和差异比较,对DPP-4抑制剂在临床的药物应用选择有重要的指导意义。在获得Expert Opinion on Pharmacotherapy杂志(Taylor&Francis Group)授权同意后,本文对2017年5月发表于该刊上的社论"DPP-4抑制剂类药物在2型糖尿病管理中的应用比较与选择"进行中文编译,并特邀山东大学齐鲁医院内分泌科陈丽教授对文稿进行点评。
Dipeptidyl-peptidase-4(DPP-4)inhibitor class is a breakthrough in the field of diabetes medication.Current market-available DPP-4 inhibitors include sitagliptin,vildagliptin,saxagliptin,linagliptin,and alogliptin.This article states and compares the efficacy,safety,application in specific population of patients and effect beyond glucose control of the class of medications.It provides important guiding significance for the clinical medication selection of DPP-4 inhibitors.This article is the Chinese translation of"Difference and choice between DPP-4 inhibitors in Type 2 diabetes management"[Expert Opinion on Pharmacotherapy,18:9,839-841],which was published in May 2017,with the permission of publisher Taylor&Francis Group and Professor Chen Li,Department of Edocrinology from Qilu Hospital of Shandong University was invited to offer her expert opinion.
作者
卡西夫.穆尼尔
伊丽莎白.拉莫斯
李艳娇
Kashif M.Munir;Elizabeth M.Lamos;LI Yan-jiao(Department of Endocrinology,Second Hospital of Shanxi Medical University,Taiyuan Shanxi 030001,China)
出处
《药品评价》
CAS
2018年第13期8-10,共3页
Drug Evaluation
关键词
糖尿病
降糖药物
DPP-4抑制剂
差异
Diabetes Mellitus
Hypoglycemic Agent
Dipeptidyl-peptidase-4 Inhibitor
Difference
